NASDAQ:PLSE Pulse Biosciences (PLSE) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free plse Stock Alerts $7.60 +0.23 (+3.12%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$7.19▼$7.8150-Day Range$6.69▼$10.8852-Week Range$3.78▼$13.62Volume129,197 shsAverage Volume179,051 shsMarket Capitalization$419.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Pulse Biosciences alerts: Email Address Ad Weiss RatingsProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself About Pulse Biosciences Stock (NASDAQ:PLSE)Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Read More PLSE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLSE Stock News HeadlinesApril 28, 2024 | insidermonkey.com5 ChatGPT Penny Stock Picks Right NowApril 24, 2024 | businesswire.comPulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024May 1, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. March 29, 2024 | finance.yahoo.comQ4 2023 Pulse Biosciences Inc Earnings CallMarch 28, 2024 | investorplace.comPLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023March 28, 2024 | finance.yahoo.comPulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023March 28, 2024 | businesswire.comPulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial ResultsMarch 28, 2024 | businesswire.comPulse Biosciences Announces Plans to Initiate a Rights OfferingMay 1, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. March 17, 2024 | finance.yahoo.comPLSE Apr 2024 25.000 callMarch 17, 2024 | finance.yahoo.comPLSE Oct 2024 17.500 callMarch 16, 2024 | finance.yahoo.comPLSE Oct 2024 12.500 callMarch 16, 2024 | finance.yahoo.comPLSE Jul 2024 2.500 putMarch 14, 2024 | businesswire.comPulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024March 13, 2024 | msn.comPulse Biosciences’s CellFXnsPFA system secures FDA 510(k) clearanceMarch 10, 2024 | investing.comFDA clears Pulse Biosciences' soft tissue ablation systemMarch 9, 2024 | markets.businessinsider.comPulse Biosciences Gets FDA 510(k) Clearance For CellFX NsPFA Percutaneous Electrode SystemMarch 8, 2024 | stockhouse.comPulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode SystemMarch 8, 2024 | businesswire.comPulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode SystemFebruary 14, 2024 | markets.businessinsider.comPulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock UpFebruary 14, 2024 | finance.yahoo.comPulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility StudyFebruary 14, 2024 | businesswire.comPulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility StudyFebruary 2, 2024 | finance.yahoo.comCompanies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In GrowthJanuary 31, 2024 | finance.yahoo.comPulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF SymposiumJanuary 6, 2024 | finance.yahoo.comInsiders of Pulse Biosciences, Inc. (NASDAQ:PLSE) must be disappointed as stock fell 26% after recent purchasesJanuary 2, 2024 | finance.yahoo.comPulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac ClampDecember 20, 2023 | finance.yahoo.comPulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac CatheterSee More Headlines Receive PLSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/01/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PLSE CUSIPN/A CIK1625101 Webwww.pulsebiosciences.com Phone(510) 906-4600FaxN/AEmployees61Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-112.74% Return on Assets-61.09% Debt Debt-to-Equity RatioN/A Current Ratio6.76 Quick Ratio6.76 Sales & Book Value Annual Sales$700,000.00 Price / Sales599.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book9.38Miscellaneous Outstanding Shares55,220,000Free Float16,733,000Market Cap$419.67 million OptionableOptionable Beta1.67 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Robert W. Duggan (Age 79)Executive Chairman Mr. Kevin P. Danahy (Age 52)President & CEO Comp: $834.73kMr. Darrin R. Uecker (Age 58)CTO & Director Comp: $834.73kMr. Mitchell E. Levinson (Age 64)Chief Strategy Officer Comp: $584.57kDr. Richard Nuccitelli Ph.D.Chief Science OfficerMr. Kenneth B. Stratton Esq. (Age 55)J.D., General Counsel & Corporate Secretary Ms. Patty PerlaVice President of Human ResourcesMr. David DanitzSenior Vice President of EngineeringDr. Gansevoort Dunnington M.D.Chief Medical OfficerDr. Niv Ad M.D.Chief Science Officer of Cardiac SurgeryMore ExecutivesKey CompetitorsOraSure TechnologiesNASDAQ:OSURBeauty HealthNASDAQ:SKINNevroNYSE:NVROAnika TherapeuticsNASDAQ:ANIKNeuroPaceNASDAQ:NPCEView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsBought 2,952 shares on 5/1/2024Ownership: 0.014%Simplex Trading LLCBought 1,900 shares on 4/25/2024Ownership: 0.000%Westside Investment Management Inc.Sold 2,015 shares on 4/19/2024Ownership: 0.058%Griffin Asset Management Inc.Bought 40,700 shares on 4/17/2024Ownership: 0.544%PNC Financial Services Group Inc.Bought 19,789 shares on 3/22/2024Ownership: 0.036%View All Insider TransactionsView All Institutional Transactions PLSE Stock Analysis - Frequently Asked Questions How have PLSE shares performed in 2024? Pulse Biosciences' stock was trading at $12.24 at the beginning of 2024. Since then, PLSE shares have decreased by 37.9% and is now trading at $7.60. View the best growth stocks for 2024 here. When is Pulse Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our PLSE earnings forecast. How can I listen to Pulse Biosciences' earnings call? Pulse Biosciences will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Pulse Biosciences' earnings last quarter? Pulse Biosciences, Inc. (NASDAQ:PLSE) issued its quarterly earnings data on Thursday, March, 28th. The company reported ($0.21) EPS for the quarter. What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO? 2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pulse Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Enphase Energy (ENPH) and Novavax (NVAX). When did Pulse Biosciences IPO? Pulse Biosciences (PLSE) raised $20 million in an initial public offering on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO. Who are Pulse Biosciences' major shareholders? Pulse Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Griffin Asset Management Inc. (0.54%), Westside Investment Management Inc. (0.06%), Simplex Trading LLC (0.00%) and BNP Paribas Financial Markets (0.01%). Insiders that own company stock include Kevin Patrick Danahy, Mitchell E Levinson and Robert W Duggan. View institutional ownership trends. How do I buy shares of Pulse Biosciences? Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PLSE) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority Gold😱 This phenomenon is smashing regular market gainsMillPubElon’s New Device is About to Shock the WorldInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingA once-in-a-century investment opportunityStansberry ResearchPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulse Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
